C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of “Moderate Buy” by Analysts

C4 Therapeutics, Inc. (NASDAQ:CCCC) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $7.75.

A number of research firms recently weighed in on CCCC. Barclays increased their price objective on C4 Therapeutics from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. raised their price target on shares of C4 Therapeutics from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. TD Cowen reaffirmed a “buy” rating on shares of C4 Therapeutics in a research report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Monday, April 20th. Finally, Wall Street Zen upgraded shares of C4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, February 28th.

Institutional Trading of C4 Therapeutics

Hedge funds have recently made changes to their positions in the stock. SummitTX Capital L.P. purchased a new position in shares of C4 Therapeutics during the first quarter valued at about $28,000. Zacks Investment Management purchased a new position in shares of C4 Therapeutics during the third quarter valued at about $29,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of C4 Therapeutics during the third quarter valued at about $43,000. Delta Investment Management LLC purchased a new position in shares of C4 Therapeutics during the fourth quarter valued at about $38,000. Finally, Virtu Financial LLC purchased a new position in shares of C4 Therapeutics during the fourth quarter valued at about $39,000. 78.81% of the stock is owned by institutional investors.

C4 Therapeutics News Summary

Here are the key news stories impacting C4 Therapeutics this week:

• Positive Sentiment: Brookline Capital Markets raised near-term earnings estimates for C4 Therapeutics, including Q2 2026, Q3 2026, and Q4 2026, suggesting improving expectations for the company’s loss trajectory. Analyst estimate update for C4 Therapeutics
• Positive Sentiment: The company’s recent quarterly report came in above analyst forecasts, with EPS and revenue both topping expectations, which may be supporting renewed investor optimism. C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets
• Neutral Sentiment: One Zacks note compared C4 Therapeutics’ year-to-date performance with other medical stocks, but it did not appear to introduce a major new catalyst. Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics Stock Performance

C4 Therapeutics stock opened at $3.56 on Tuesday. C4 Therapeutics has a 52 week low of $1.21 and a 52 week high of $3.95. The stock has a market capitalization of $393.63 million, a P/E ratio of -2.99 and a beta of 2.77. The stock has a 50-day simple moving average of $2.88 and a 200 day simple moving average of $2.49.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.05. C4 Therapeutics had a negative net margin of 297.76% and a negative return on equity of 50.68%. The business had revenue of $6.15 million during the quarter, compared to the consensus estimate of $4.42 million. Research analysts forecast that C4 Therapeutics will post -0.87 earnings per share for the current year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.